ClinicalTrials.gg
CompletedNCT02602483Updated Jan 19, 2017

Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).

A Phase 1/2 interventional study of Ibuprofen and Magnesium in Temporomandibular Joint Disorders, sponsored by Spherium Biomed. Completed at 4 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-19.

Sponsored by Spherium Biomed · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Temporomandibular Joint Disorders with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Temporomandibular Joint Disorders · Spain.

Enrollment
4th of 32
96 · median 53
Started
2015
with 2 others
Phase 1/2
2 of 40
none open now
Registered
3rd of 40
by date

Among the 40 studies in Temporomandibular Joint Disorders with a site in Spain, this one is the 4th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2015, is one of 2 in phase 1/2, and was the 3rd registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

12 of the 40 studies in Temporomandibular Joint Disorders with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Temporomandibular Joint Disorders with a site in Spain, or all of them as a file.
02

Study summary

The objetive of this study is to explore the efficacy and safety of a triple combination of ibuprofen, magnesium and ascorbic acid for acute pain treatment in TMJD patients

03

Conditions studied

  • Temporomandibular Joint Disorders

Keywords

  • temporomandibular
  • joint
  • pain
  • ibuprofen
  • magnesium
  • vitamin C
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. TMD dysfunction syndrome patients of RDC/TMD Groups Ia and/or Ib (+/- IIIa and/or IIIb); with moderate to severe pain (VAS >4), to conservative treatment (including splint / local prosthesis)
  2. Subjects between 18 and 65 years.
  3. Body weight within the normal range (IMC index between 19 and 30) expressed as weight (kg) /height (m2).
  4. Physical condition according to (American Society of Anesthesiologists)
  5. Having not participated in previous clinical trial during the three months preceding the setting-up of this study.
  6. Free acceptance to collaborate in the study, expressed by signature of written by the participant

Exclusion criteria

Exclusion Criteria:

  1. Patients who are pregnant or breastfeeding.
  2. Patients who have a consumption of enzyme-inducing drugs within the 30 days prior to the study: carbamazepinam, nevirapine, phenobarbital, rifampin, secobarbital and St. John's wort.
  3. Patients who are consuming: acetaminophen, acetyl salicylic acid, bemiparina, clonixidina, oral anticoagulant, heparin and derivatives, systemic , pemetresed, digoxin, phenytoin, lithium, methotrexate, Salicylates, NSAIDs, antacids containing aluminum, such as algeldrato, magaldrate, morphine and its derivatives.

    Patients who have been medicated with NSAIDs or Morphic derivatives for the treatment of pain of TMD prior to attending the consultation will be included whether, they meet a of 8 to 12 hours (depending on the medication taken) before being included in the study.

  4. Patients with underlying systemic pathology candidate to receive drug treatment with analgesic.
  5. In patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. Peptic ulcer / active or recurrent gastrointestinal hemorrhage (two or more episodes of ulceration) or proven hemorrhage.
  6. Patients with active Ulcerative colitis or Crohn's disease. Severe heart failure. Severe renal dysfunction. Severe hepatic dysfunction.
  7. Patients with urolithiasis by oxalate
  8. History of alcoholism or drug dependence within 3 months prior to the screening visit, and / or, History of psychotropic drugs consumption within 3 months prior to the screening visit.
  9. Heavy consumer of stimulating beverages (>5 coffees, teas, or cola drinks per day).
  10. History of drug allergy, idiosyncrasy or . 11 Patients with cerebrovascular bleeding or other active bleeding 12 Patients with bleeding diathesis or other bleeding disorders .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Triple combination

    Powder for oral administration

    Drug: Ibuprofen · Drug: Magnesium · Drug: Ascorbic Acid

  • Active comparator
    Ibuprofen

    Powder for oral administration

    Drug: Ibuprofen

  • Active comparator
    Magnesium + ascorbic acid

    Powder for oral administration

    Drug: Magnesium · Drug: Ascorbic Acid

  • Placebo comparator
    Placebo

    Powder for oral administration

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Pain level from baseline compared to placebo assessed by a pain VAS scale

    Pain level is measured according to visual analogue scale (VAS, 0-100 mm) before and 7 days after treatment.

    Time frame: seven days

Secondary outcomes

  1. Change from baseline compared to placebo assessed by RDC/TMD questionnaire at day 3 +/-1 and at day 7.

    Time frame: seven days

07

Study locations

4 sites
  • Clinica Universitaria Odontològica de la Universitat Internacional de Catalunya
    Sant Cugat del Valles, Barcelona 08195, Spain
  • Hospital Universitario Rey Juan Carlos
    Móstoles, Madrid 28933, Spain
  • Hospital Odontològic de la Universitat de Barcelona
    Barcelona, 08027, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 11, 2015
Start
Dec 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Jan 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02602483
Lead sponsor
Spherium Biomed
Collaborators
Universitat Internacional de Catalunya, Hospital Odontològic UB, Hospital Universitario La Fe, Hospital Universitario Rey Juan Carlos
Responsible party
Sponsor
First posted
Nov 11, 2015
Start date
Dec 2015
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Jan 19, 2017

Study contacts

Giner Lluis, MD
principal investigator · Clinica Universitaria Odontologica de la Universidad Internacional de Cataluña

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Ascorbic Acid

Start the discussion